Bridging 30 years of hormone optimization experience from men's health to women's wellness
| Key Takeaways • FDA removes black box warnings: In November 2025, the FDA initiated removal of the 22-year-old boxed warnings from menopausal hormone therapy products, acknowledging that benefits outweigh risks for most women under 60. • The Timing Hypothesis matters: Starting hormone replacement within 10 years of menopause onset is associated with significant reductions in cardiovascular events, fractures, and all-cause mortality. • Testosterone isn't just for men: Women lose about 70% of their testosterone by age 40. Global clinical consensus supports testosterone therapy for Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women. • Transdermal delivery is preferred: Patches, gels, and creams bypass liver metabolism, avoiding the clotting and stroke risks linked to older oral formulations. • GSM is progressive: Genitourinary Syndrome of Menopause affects up to 84% of postmenopausal women and worsens without treatment. Unlike hot flashes, it doesn't resolve on its own. • Bio-identical hormones are distinct: Structurally identical to human hormones, bio-identical estradiol and micronized progesterone carry a different safety profile than the synthetic formulations used in the original WHI study. |
Download Article
Last edited:
Start Here (3K views)
